Martin Tolstrup

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/966858/publications.pdf

Version: 2024-02-01

110 papers	4,715 citations	117571 34 h-index	110317 64 g-index
118 all docs	118 docs citations	118 times ranked	5849 citing authors

#	Article	IF	Citations
1	Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. Lancet HIV,the, 2014, 1, e13-e21.	2.1	542
2	The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo. PLoS Pathogens, 2015, 11, e1005142.	2.1	445
3	International AIDS Society global scientific strategy: towards an HIV cure 2016. Nature Medicine, 2016, 22, 839-850.	15.2	395
4	Comparison of HDAC inhibitors in clinical development. Human Vaccines and Immunotherapeutics, 2013, 9, 993-1001.	1.4	173
5	Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B/2A trial. Lancet HIV,the, 2016, 3, e463-e472.	2.1	159
6	Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial.. EClinicalMedicine, 2021, 35, 100849.	3.2	146
7	Short-Course Toll-Like Receptor 9 Agonist Treatment Impacts Innate Immunity and Plasma Viremia in Individuals With Human Immunodeficiency Virus Infection. Clinical Infectious Diseases, 2017, 64, 1686-1695.	2.9	122
8	SARS-CoV-2 persistence is associated with antigen-specific CD8 T-cell responses. EBioMedicine, 2021, 64, 103230.	2.7	113
9	A Novel Toll-Like Receptor 9 Agonist, MGN1703, Enhances HIV-1 Transcription and NK Cell-Mediated Inhibition of HIV-1-Infected Autologous CD4 ⁺ T Cells. Journal of Virology, 2016, 90, 4441-4453.	1.5	94
10	HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Daysâ€"Implications for HIV Remission. PLoS Pathogens, 2015, 11, e1005000.	2.1	92
11	Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat. Journal of Virology, 2015, 89, 10176-10189.	1.5	89
12	Reversal of Latency as Part of a Cure for HIV-1. Trends in Microbiology, 2016, 24, 90-97.	3.5	88
13	Comparison of the Immunogenicity and Reactogenicity of Cervarix and Gardasil Human Papillomavirus Vaccines in HIV-Infected Adults: A Randomized, Double-Blind Clinical Trial. Journal of Infectious Diseases, 2014, 209, 1165-1173.	1.9	66
14	Effects of 24-week Toll-like receptor 9 agonist treatment in HIV type 1+ individuals. Aids, 2019, 33, 1315-1325.	1.0	66
15	Tenofovir Selectively Regulates Production of Inflammatory Cytokines and Shifts the IL-12/IL-10 Balance in Human Primary Cells. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 57, 265-275.	0.9	65
16	Broad activation of latent HIV-1 in vivo. Nature Communications, 2016, 7, 12731.	5.8	65
17	Transmission of HIVâ€1 Drugâ€Resistant Variants: Prevalence and Effect on Treatment Outcome. Clinical Infectious Diseases, 2010, 50, 566-573.	2.9	63
18	Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Survey Among 17 971 Healthcare and Administrative Personnel at Hospitals, Prehospital Services, and Specialist Practitioners in the Central Denmark Region. Clinical Infectious Diseases, 2021, 73, e2853-e2860.	2.9	60

#	Article	IF	Citations
19	HDAC inhibition induces HIV-1 protein and enables immune-based clearance following latency reversal. JCI Insight, 2017, 2, .	2.3	59
20	Inflammation and Platelet Activation After COVID-19 Vaccines - Possible Mechanisms Behind Vaccine-Induced Immune Thrombocytopenia and Thrombosis. Frontiers in Immunology, 2021, 12, 779453.	2.2	59
21	SARS-CoV-2 elicits robust adaptive immune responses regardless of disease severity. EBioMedicine, 2021, 68, 103410.	2.7	56
22	IL-1R3 blockade broadly attenuates the functions of six members of the IL-1 family, revealing their contribution to models of disease. Nature Immunology, 2019, 20, 1138-1149.	7.0	55
23	Comparison of Bone and Renal Effects In HIV-infected Adults Switching to Abacavir or Tenofovir Based Therapy in a Randomized Trial. PLoS ONE, 2012, 7, e32445.	1.1	53
24	Administration of a Toll-Like Receptor 9 Agonist Decreases the Proviral Reservoir in Virologically Suppressed HIV-Infected Patients. PLoS ONE, 2013, 8, e62074.	1.1	49
25	Characterization of Intact Proviruses in Blood and Lymph Node from HIV-Infected Individuals Undergoing Analytical Treatment Interruption. Journal of Virology, 2019, 93, .	1.5	49
26	TLR2 and TLR7 mediate distinct immunopathological and antiviral plasmacytoid dendritic cell responses to SARSâ€CoVâ€2 infection. EMBO Journal, 2022, 41, e109622.	3.5	46
27	Comparison of the immunogenicity of Cervarix^{Â®}and Gardasil^{Â®}human papillomavirus vaccines for oncogenic non-vaccine serotypes HPV-31, HPV-33, and HPV-45 in HIV-infected adults. Human Vaccines and Immunotherapeutics, 2014, 10, 1147-1154.	1.4	45
28	Macromolecular Antiviral Agents against Zika, Ebola, SARS, and Other Pathogenic Viruses. Advanced Healthcare Materials, 2017, 6, 1700748.	3.9	45
29	T Cells Detect Intracellular DNA but Fail to Induce Type I IFN Responses: Implications for Restriction of HIV Replication. PLoS ONE, 2014, 9, e84513.	1.1	45
30	Eliminating the latent HIV reservoir by reactivation strategies: Advancing to clinical trials. Human Vaccines and Immunotherapeutics, 2013, 9, 790-799.	1.4	44
31	The Use of Toll-Like Receptor Agonists in HIV-1 Cure Strategies. Frontiers in Immunology, 2020, 11, 1112.	2.2	44
32	Activation of Latent Human Immunodeficiency Virus by the Histone Deacetylase Inhibitor Panobinostat: A Pilot Study to Assess Effects on the Central Nervous System. Open Forum Infectious Diseases, 2015, 2, ofv037.	0.4	42
33	Human Papillomavirus neutralizing and cross-reactive antibodies induced in HIV-positive subjects after vaccination with quadrivalent and bivalent HPV vaccines. Vaccine, 2016, 34, 1559-1565.	1.7	42
34	Albuminâ€“Polymerâ€“Drug Conjugates: Long Circulating, High Payload Drug Delivery Vehicles. ACS Macro Letters, 2016, 5, 1089-1094.	2.3	34
35	Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial. Lancet Microbe, The, 2022, 3, e203-e214.	3.4	33
36	Interleukin-37 Expression Is Increased in Chronic HIV-1-Infected Individuals and Is Associated with Inflammation and the Size of the Total Viral Reservoir. Molecular Medicine, 2015, 21, 337-345.	1.9	32

#	Article	IF	Citations
37	Characterization of the HIV-1 transcription profile after romidepsin administration in ART-suppressed individuals. Aids, 2019, 33, 425-431.	1.0	31
38	Endotoxemia Is Associated with Altered Innate and Adaptive Immune Responses in Untreated HIV-1 Infected Individuals. PLoS ONE, 2011, 6, e21275.	1.1	30
39	Macromolecular (pro)drugs in antiviral research. Polymer Chemistry, 2014, 5, 6407-6425.	1.9	30
40	Disulfide reshuffling triggers the release of a thiol-free anti-HIV agent to make up fast-acting, potent macromolecular prodrugs. Chemical Communications, 2014, 50, 14498-14500.	2.2	30
41	ART influences HIV persistence in the female reproductive tract and cervicovaginal secretions. Journal of Clinical Investigation, 2016, 126, 892-904.	3.9	30
42	Characteristics associated with serological COVID-19 vaccine response and durability in an older population with significant comorbidity: the Danish Nationwide ENFORCE Study. Clinical Microbiology and Infection, 2022, 28, 1126-1133.	2.8	30
43	Romidepsin-induced HIV-1 viremia during effective antiretroviral therapy contains identical viral sequences with few deleterious mutations. Aids, 2017, 31, 771-779.	1.0	29
44	Histone Deacetylase Inhibitor Romidepsin InhibitsDe NovoHIV-1 Infections. Antimicrobial Agents and Chemotherapy, 2015, 59, 3984-3994.	1.4	26
45	Vaccination against oncogenic human papillomavirus infection in HIV-infected populations: review of current status and future perspectives. Sexual Health, 2014, 11, 511.	0.4	25
46	Macromolecular prodrugs of ribavirin: towards a treatment for co-infection with HIV and HCV. Chemical Science, 2015, 6, 264-269.	3.7	25
47	Highly Active Macromolecular Prodrugs Inhibit Expression of the Hepatitis C Virus Genome in the Host Cells. Advanced Healthcare Materials, 2015, 4, 65-68.	3.9	25
48	Evaluation of cardiovascular biomarkers In HIV-infected patients switching to abacavir or tenofovir based therapy. BMC Infectious Diseases, 2011, 11, 267.	1.3	24
49	Full fusion competence rescue of the enfuvirtide resistant HIV-1 gp41 genotype (43D) by a prevalent polymorphism (137K). Aids, 2007, 21, 519-521.	1.0	22
50	TLR9 agonist MGN1703 enhances B cell differentiation and function in lymph nodes. EBioMedicine, 2019, 45, 328-340.	2.7	22
51	Persistent Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Host Displaying Treatment Induced Viral Evolution. Open Forum Infectious Diseases, 2021, 8, ofab295.	0.4	22
52	In-vivo administration of histone deacetylase inhibitors does not impair natural killer cell function in HIV+ individuals. Aids, 2019, 33, 605-613.	1.0	21
53	Modeling of Experimental Data Supports HIV Reactivation from Latency after Treatment Interruption on Average Once Every 5â€“8 Days. PLoS Pathogens, 2016, 12, e1005740.	2.1	21
54	HIV / SIV Escape from Immune Surveillance: Focus on Nef. Current HIV Research, 2004, 2, 141-151.	0.2	20

#	Article	IF	Citations
55	The Impact of B-Cell Perturbations on Pneumococcal Conjugate Vaccine Response in HIV-Infected Adults. PLoS ONE, 2012, 7, e42307.	1.1	20
56	The histone deacetylase inhibitor panobinostat lowers biomarkers of cardiovascular risk and inflammation in HIV patients. Aids, 2015, 29, 1195-1200.	1.0	20
57	Triple Activity of Lamivudine Releasing Sulfonated Polymers against HIV-1. Molecular Pharmaceutics, 2016, 13, 2397-2410.	2.3	20
58	Polymers Fight HIV: Potent (Pro)Drugs Identified Through Parallel Automated Synthesis. Advanced Healthcare Materials, 2015, 4, 46-50.	3.9	19
59	High level of HIV-1 drug resistance among patients with HIV-1 and HIV-1/2 dual infections in Guinea-Bissau. Virology Journal, 2015, 12, 41.	1.4	19
60	HIV-1 transcriptional activity during frequent longitudinal sampling in aviremic patients on antiretroviral therapy. Aids, 2016, 30, 713-721.	1.0	19
61	HIV Antibody Fc N-Linked Glycosylation Is Associated with Viral Rebound. Cell Reports, 2020, 33, 108502.	2.9	19
62	Treatment of HIV-Infected Individuals with the Histone Deacetylase Inhibitor Panobinostat Results in Increased Numbers of Regulatory T Cells and Limits Ex Vivo Lipopolysaccharide-Induced Inflammatory Responses. MSphere, 2018, 3, .	1.3	17
63	Non-covalent hitchhiking on endogenous carriers as a protraction mechanism for antiviral macromolecular prodrugs. Journal of Controlled Release, 2019, 294, 298-310.	4.8	17
64	HIV anti-latency treatment mediated by macromolecular prodrugs of histone deacetylase inhibitor, panobinostat. Chemical Science, 2016, 7, 2353-2358.	3.7	16
65	TLR9-adjuvanted pneumococcal conjugate vaccine induces antibody-independent memory responses in HIV-infected adults. Human Vaccines and Immunotherapeutics, 2012, 8, 1042-1047.	1.4	15
66	Using animal models to overcome temporal, spatial and combinatorial challenges in HIV persistence research. Journal of Translational Medicine, 2016, 14, 44.	1.8	15
67	Multiple Homozygous Variants in the STING-Encoding TMEM173 Gene in HIV Long-Term Nonprogressors. Journal of Immunology, 2018, 200, 3372-3382.	0.4	15
68	Long-Acting, Potent Delivery of Combination Antiretroviral Therapy. ACS Macro Letters, 2018, 7, 587-591.	2.3	15
69	Cellular immunogenicity of human papillomavirus vaccines Cervarix and Gardasil in adults with HIV infection. Human Vaccines and Immunotherapeutics, 2018, 14, 909-916.	1.4	15
70	Antiviral and Immunological Effects of Tenofovir Microbicide in Vaginal Herpes Simplex Virus 2 Infection. AIDS Research and Human Retroviruses, 2012, 28, 1404-1411.	0.5	14
71	Anti-HIV-1 ADCC Antibodies following Latency Reversal and Treatment Interruption. Journal of Virology, 2017, 91, .	1.5	14
72	Macromolecular Prodrugs of Ribavirin: Structureâ€"Function Correlation as Inhibitors of Influenza Infectivity. Molecular Pharmaceutics, 2017, 14, 234-241.	2.3	14

#	Article	IF	Citations
73	Impacts of HIV Cure Interventions on Viral Reservoirs in Tissues. Frontiers in Microbiology, 2019, 10, 1956.	1.5	14
74	Macromolecular prodrugs of ribavirin: Polymer backbone defines blood safety, drug release, and efficacy of anti-inflammatory effects. Journal of Controlled Release, 2018, 275, 53-66.	4.8	13
75	Fimepinostat, a novel dual inhibitor of HDAC and PI3K, effectively reverses HIV-1 latency ex vivo without T cell activation. Journal of Virus Eradication, 2019, 5, 133-137.	0.3	13
76	Estimating Initial Viral Levels during Simian Immunodeficiency Virus/Human Immunodeficiency Virus Reactivation from Latency. Journal of Virology, 2018, 92, .	1.5	12
77	Whole Exome Sequencing of HIV-1 long-term non-progressors identifies rare variants in genes encoding innate immune sensors and signaling molecules. Scientific Reports, 2018, 8, 15253.	1.6	12
78	Immune checkpoints and the HIV-1 reservoir: proceed with caution. Journal of Virus Eradication, 2016, 2, 183-6.	0.3	12
79	Polyanionic Macromolecular Prodrugs of Ribavirin: Antiviral Agents with a Broad Spectrum of Activity. Advanced Healthcare Materials, 2016, 5, 534-540.	3.9	11
80	Entecavir Therapy Induces de Novo HIV Reverseâ€Transcriptase M184V Mutation in an Antiretroviral Therapyâ€“Naive Patient. Clinical Infectious Diseases, 2008, 46, e88-e91.	2.9	10
81	Administration of Panobinostat Is Associated with Increased IL-17A mRNA in the Intestinal Epithelium of HIV-1 Patients. Mediators of Inflammation, 2015, 2015, 1-11.	1.4	10
82	The potential role for romidepsin as a component in early HIV-1 curative efforts. Expert Review of Anti-Infective Therapy, 2016, 14, 447-450.	2.0	10
83	Genetic characterization of the HIV-1 reservoir after Vacc-4x and romidepsin therapy in HIV-1-infected individuals. Aids, 2018, 32, 1793-1802.	1.0	10
84	The Potential of Long-Acting, Tissue-Targeted Synthetic Nanotherapy for Delivery of Antiviral Therapy Against HIV Infection. Viruses, 2020, 12, 412.	1.5	10
85	Timing of Toll-Like Receptor 9 Agonist Administration in Pneumococcal Vaccination Impacts Both Humoral and Cellular Immune Responses as Well as Nasopharyngeal Colonization in Mice. Infection and Immunity, 2012, 80, 1744-1752.	1.0	8
86	Cysteine 138 mutation in HIV-1 Nef from patients with delayed disease progression. Sexual Health, 2006, 3, 281.	0.4	7
87	Levels of regulatory B cells do not predict serological responses to hepatitis B vaccine. Human Vaccines and Immunotherapeutics, 2018, 14, 1483-1488.	1.4	7
88	Comparable human reconstitution following Cesium-137 versus X-ray irradiation preconditioning in immunodeficient NOG mice. PLoS ONE, 2020, 15, e0241375.	1.1	7
89	<scp>cAIMP</scp> administration in humanized mice induces a chimerizationâ€levelâ€dependent <scp>STING</scp> response. Immunology, 2019, 157, 163-172.	2.0	6
90	Humanized NOG Mice for Intravaginal HIV Exposure and Treatment of HIV Infection. Journal of Visualized Experiments, 2020, , .	0.2	6

#	Article	IF	Citations
91	Candidate host epigenetic marks predictive for HIV reservoir size, responsiveness to latency reversal, and viral rebound. Aids, 2021, 35, 2269-2279.	1.0	6
92	Fimepinostat, a novel dual inhibitor of HDAC and PI3K, effectively reverses HIV-1 latency without T cell activation. Journal of Virus Eradication, 2019, 5, 133-137.	0.3	6
93	Population-based study of diagnostic assays for Borrelia infection: comparison of purified flagella antigen assay (Ideiaâ„¢, Dako Cytomation) and recombinant antigen assay (LiaisonÂ®, DiaSorin). BMC Clinical Pathology, 2008, 8, 4.	1.8	5
94	Anti-inflammatory effect of a retrovirus-derived immunosuppressive peptide in mouse models. BMC Immunology, 2013, 14, 51.	0.9	5
95	Nucleic Acids as a Natureâ€Inspired Scaffold for Macromolecular Prodrugs of Nucleoside Analogues. Advanced Science, 2019, 6, 1802095.	5.6	5
96	Symptoms reported by SARS-CoV-2 seropositive and seronegative healthcare and administrative employees in Denmark from May to August 2020. International Journal of Infectious Diseases, 2021, 109, 17-23.	1.5	5
97	Effect of Age on Innate and Adaptive Immunity in Hospitalized COVID-19 Patients. Journal of Clinical Medicine, 2021, 10, 4798.	1.0	5
98	Epigenetic landscape in the kick-and-kill therapeutic vaccine BCN02 clinical trial is associated with antiretroviral treatment interruption (ATI) outcome. EBioMedicine, 2022, 78, 103956.	2.7	5
99	Beyond antiretroviral therapy. Aids, 2017, 31, 1665-1667.	1.0	4
100	Synthetic Polymer with a Structure-Driven Hepatic Deposition and Curative Pharmacological Activity in Hepatic Cells. ACS Macro Letters, 2017, 6, 935-940.	2.3	4
101	HIV-1 Reverse Transcriptase Gene 103K/N and 184M/V Combinations in Tandem. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 41, 160-167.	0.9	3
102	Induction of humoral and cellular immune responses against the HIV-1 envelope protein using Î³-retroviral virus-like particles. Virology Journal, 2011, 8, 381.	1.4	3
103	Construction of a Gammaretrovirus with a Novel Tropism and Wild-Type Replication Kinetics Capable of Using Human APJ as Entry Receptor. Journal of Virology, 2012, 86, 10621-10627.	1.5	3
104	The Impact of IFNÎ»4 on the Adaptive Immune Response to SARS-CoV-2 Infection. Journal of Interferon and Cytokine Research, 2021, 41, 407-414.	0.5	3
105	New insights on the phenotype of HIV reservoirs. Aids, 2016, 30, 1675-1676.	1.0	2
106	Differences in antiretroviral regimens do not impact safety or level of latency reversal in persons receiving romidepsin. Aids, 2018, 32, 1729-1731.	1.0	1
107	Modest de novo Reactivation of Single HIV-1 Proviruses in Peripheral CD4+ T Cells by Romidepsin. Frontiers in Virology, 2021, 1, .	0.7	1
108	CD169 (Siglec-1) as a Robust Human Cell Biomarker of Toll-Like Receptor 9 Agonist Immunotherapy. Frontiers in Cellular and Infection Microbiology, 0, 12, .	1.8	1

#	Article	IF	Citations
109	Editorial Commentary: Reversing Latency in HIV-Infected Patients. Clinical Infectious Diseases, 2014, 58, 891-892.	2.9	0
110	HIV-1 acquisition in a man with ulcerative colitis on anti-Î±4Î²7 mAb vedolizumab treatment. Aids, 2020, 34, 1689-1692.	1.0	0